Bioquímica y Biología Molecular y Fisiología
Departamento
![Foto de Yolanda](/img/nophoto.png)
Yolanda
Arias Piedras
Publicaciones en las que colabora con Yolanda Arias Piedras (8)
2013
-
In vitro and in vivo effects of an anti-mouse endoglin (CD105)-immunotoxin on the early stages of mouse B16MEL4A5 melanoma tumours
Cancer Immunology, Immunotherapy, Vol. 62, Núm. 3, pp. 541-551
2012
-
Transient injury-dependent up-regulation of CD105 and its specific targeting with an anti-vascular anti-mouse endoglin-nigrin b immunotoxin
Medicinal Chemistry, Vol. 8, Núm. 6, pp. 996-1002
2007
-
Targeting a marker of the tumour neovasculature using a novel anti-human CD105-immunotoxin containing the non-toxic type 2 ribosome-inactivating protein nigrin b
Cancer Letters, Vol. 256, Núm. 1, pp. 73-80
2005
-
Cytotoxicity of an ebulin l-anti-human CD105 immunotoxin on mouse fibroblasts (L929) and rat myoblasts (L6E9) cells expressing human CD105.
Medicinal chemistry, Vol. 1, Núm. 1, pp. 65-70
-
Specific dose-dependent damage of Lieberkühn crypts promoted by large doses of type 2 ribosome-inactivating protein nigrin b intravenous injection to mice
Toxicology and Applied Pharmacology, Vol. 207, Núm. 2, pp. 138-146
2004
-
Utilización de la proteína inactivadora de ribosomas nigrina b en la construcción de inmunotoxinas contra la vasculatura tumoral
Utilización de la proteína inactivadora de ribosomas nigrina b en la construcción de inmunotoxinas contra la vasculatura tumoral
2003
-
Non-toxic type 2 ribosome-inactivating proteins (RIPs) from Sambucus: occurrence, cellular and molecular activities and potential uses.
Cellular and molecular biology (Noisy-le-Grand, France), Vol. 49, Núm. 4, pp. 537-545
2001
-
Sensitivity of cancer cell lines to the novel non-toxic type 2 ribosome-inactivating protein nigrin b
Cancer Letters, Vol. 167, Núm. 2, pp. 163-169